Last reviewed · How we verify
Atripla or Stribild
Atripla and Stribild are fixed-dose combination antiretroviral drugs that inhibit HIV replication through multiple mechanisms targeting reverse transcriptase and integrase.
Atripla and Stribild are fixed-dose combination antiretroviral drugs that inhibit HIV replication through multiple mechanisms targeting reverse transcriptase and integrase. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients (Atripla), HIV-1 infection in treatment-naïve patients (Stribild).
At a glance
| Generic name | Atripla or Stribild |
|---|---|
| Also known as | (alternate: Truvada + 3rd ARV) |
| Sponsor | Fred Hutchinson Cancer Center |
| Drug class | Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based) |
| Target | HIV reverse transcriptase, HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Atripla combines efavirenz (a non-nucleoside reverse transcriptase inhibitor), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir (a nucleotide reverse transcriptase inhibitor) to block HIV reverse transcriptase. Stribild combines elvitegravir (an integrase strand transfer inhibitor), emtricitabine, and tenofovir to target both integrase and reverse transcriptase. Both regimens work synergistically to suppress HIV viral replication and reduce viral load.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients (Atripla)
- HIV-1 infection in treatment-naïve patients (Stribild)
Common side effects
- Dizziness or CNS effects
- Nausea
- Headache
- Rash
- Renal impairment or proteinuria
- Bone density loss
Key clinical trials
- HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (PHASE4)
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (PHASE3)
- Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atripla or Stribild CI brief — competitive landscape report
- Atripla or Stribild updates RSS · CI watch RSS
- Fred Hutchinson Cancer Center portfolio CI